Veeda Clinical Research Unlisted Shares Share Price
About The Company
Veeda Clinical Research Unlisted Shares Unlisted Shares
Financials · IPO timeline · Growth projects
Strong
Market Position
Consistent
YoY Growth
Experienced
Management
Key Indicators
A snapshot of Veeda Clinical Research Unlisted Shares's financial health, valuation multiples and capital efficiency at a glance.
Pricing Trends
Financial Performance
| Indicators | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 621.1 | 293.0 | 311.3 | 293.1 | 234.3 |
| Expense | 484.7 | 247.4 | 247.0 | 209.8 | 129.1 |
| EBITDA | 136.4 | 45.6 | 64.3 | 83.3 | 105.2 |
| Other Cost | 202.0 | 40.9 | 28.8 | 17.7 | 20.0 |
| PBT | -65.5 | 4.7 | 35.5 | 65.6 | 85.2 |
| Tax Expense | 1.3 | 1.6 | 11.1 | 15.5 | 22.2 |
| PAT | -66.8 | 3.1 | 24.4 | 50.1 | 63.0 |
| Other Inc./Exp. | 8.4 | -0.1 | -0.4 | 0.3 | -0.1 |
| Net Income | -58.4 | 3.0 | 24.0 | 50.4 | 62.9 |
| Shares O/S | 6.58 | 6.30 | 3.60 | 3.60 | 3.60 |
| EPS (₹) | -10.57 | 0.50 | 7.60 | 10.30 | 15.40 |
| Rev. Growth % | 112.0% | -5.9% | 6.2% | 25.1% | — |
| EBITDA Mgn % | 22.0% | 15.6% | 20.7% | 28.4% | 44.9% |
| Net Mgn % | -9.4% | 1.0% | 7.7% | 17.2% | 26.8% |
| EPS Growth | -2214.0% | -93.4% | -26.2% | -33.1% | — |
Registered Address
Management Team
Download Financial Results
In The News
Top Unlisted companies
Frequently Asked Questions
Still have questions?
Our expert team typically responds within 30 minutes during market hours.
Veeda Clinical Research Unlisted Shares Unlisted Shares
About Veeda Clinical Research Unlisted Shares
Veeda Clinical Research Limited is one of India's largest and well-known Clinical Research Organisations (CRO). They specialise in providing clinical services to global pharma and biotech industries.
Business Model Of Veeda Clinical
Bioavailability & Bioequivalence Studies(BA & BS): With the largest healthy volunteer databases and advanced infrastructure spread across three clinical facilities, Veeda Clinical delivers precision in pharmacokinetic (PK) and pharmacodynamics (PD) studies of drugs.
Pre-Clinical & Clinical Trials: Comprises of conducting Pre-clinical, Clinical Phase I, Phase II, Phase III & Phase IV Trials
Bio Analysis: Involves Bio support in Method Development, Method Validation and Sample analysis of the drug.
Pharma Vigilance: Veeda brings in quality management systems, Inspection readiness and compliance support to mitigate risks in clinical trials.
Medical Writing: Preparing clear, accurate documentation for Regulatory Compliance.
Clientage
Veeda Clinical has served a variety of global clients including major pharma companies like Mankind Pharma, Dr Reddy Laboratories and Granules India. Their international clients include Laboritorios Licensa in Europe & Novugen Pharma in Malaysia.
Recent Strategic Developments
Acquisition of Heads: In 2024 Veeda Clinical Acquired European CRO Heads, which specialises in Oncology Clinical Trials. Heads have 25 locations across Europe, North America and Asia Pacific Markets. Thus positioning Veeda as a global CRO.
Acquisition of Bioneeds: In 2021, Heads Acquired a 50.1% stake in Bengaluru-based pre-clinical CRO Bioneeds for an undisclosed amount.
Joint Venture with Somru BioScience: Launched Ingenuity BioSciences to focus on biosimilars.
Plan To Raise Rs 185 Crore From IPO-Refiles DRHP In 2025
Veeda Clinical has refiled its Draft Red Herring Prospectus (DRHP) in 2025. This planned IPO will have a face value of Rs 2 per share and combines a fresh issue of shares worth Rs 185 crore and an Offer for Sale for 13 Million Equity Shares by existing shareholders.
Analysis of Veeda Unlisted Share Price
In March 2025, the Veeda unlisted share price climbed to around Rs 520, possibly due to expectations of strong annual results.
· Throughout April, the stock saw a slow but consistent drop from Rs 520 to around Rs 495. This decline may reflect growing investor caution, perhaps due to the anticipation of weaker financial results
· A noticeable fall occurred in early May, with the Veeda Clinical Research share price dropping to approximately ₹480. This coincides with the likely release of FY 2023-24 financial results, where the company reported a net loss and negative EPS.
· Overall, from a peak of Rs 520 in March to Rs 470 in August, the stock lost about Rs 50 per share, representing a 9.6% decline over six months. This decline in Veeda clinical research unlisted share price closely mirrors the company’s deteriorating financial performance.
Veeda Clinical Research Unlisted Shares Financial Analysis
Particulars | FY 2024-25 | FY 2023-24 | FY 2022-23 |
Revenue | Rs 610 cr | Rs 388 cr | Rs 409 cr |
EBITDA | Rs 136 cr | Rs 71.2 cr | Rs 114 cr |
Net Income | Rs (67) cr | Rs (3.58) cr | Rs 42 cr |
EPS | Rs (10.19) | Rs (0.04) | Rs 8 |
A) Revenue Growth
The company’s revenue rebounded sharply in FY 2024-25, rising 57% to Rs 610 cr compared to Rs 388 cr in FY 2023-24. This recovery follows a mild decline of 5% in FY 2023-24 from Rs 409 cr in FY 2022-23.
This reflects a growth in the operations of Veeda Clinical Research Unlisted Shares.
B) EBITDA
EBITDA rose strongly in FY 2024-25 to Rs 136 cr, an increase of 91% compared to Rs 71.2 cr in FY 2023-24, signalling operational recovery. However, compared to Rs 114 cr in FY 2022-23, the growth is moderate (19%). Despite this improvement, sustained consistency is needed to restore confidence in operating efficiency and stabilise the Veeda unlisted share price.
C) Profit Margin
Veeda’s Operating profit margin has decreased in the last 3 years. In Fy 22, the Operating Profit margin was 21.53%, In Fy 23, the OPM grew to 25% but reduced to 13. 66% in Fy 24. In FY 25 the operating profit margin increased to 20.49%
This is still a decent profitability rate for Veeda Clinical Research unlisted shares.
D) Profit after Tax
Net income worsened significantly, with losses deepening to Rs (67) cr in FY 2024-25 compared to a small loss of Rs (3.58) cr in FY 2023-24. This represents a sharp deterioration from the Rs 42 cr profit in FY 2022-23.
The complete erosion of profitability and back-to-back losses are red flags that could exert strong downward pressure on Veeda Clinical Research unlisted share price.
E) Earnings Per Share
EPS fell further into negative territory at Rs (10.19) in FY 2024-25, compared to Rs (0.04) in FY 2023-24 and Rs 8 in FY 2022-23. The steep decline in EPS highlights worsening shareholder returns, and such negative earnings trends typically weigh heavily on Veeda’s valuation in the unlisted market.
Earnings per share and P/E Ratio affect the Veeda Clinical Research stock price.
Thus, based on the above financial observations, Veeda Clinical Research Unlisted Shares can give significant investment growth to investors, but investors need to keep all indicators in check.
How To Apply For Veeda Clinical Research Unlisted Shares Online?
Buying and selling unlisted shares can be complex if you’re not aware of the process correctly. If you’re considering buying Veeda Clinical Research Unlisted Shares and need help with how to go about it, India’s best unlisted shares broking platforms are here to help.
There are many factors to consider before applying to unlisted shares, including EPS growth, KPI, EBITDA Margin, Profit & Loss summary, etc. The experts at Stockify will provide you with every valuable piece of information you need.
Check Veeda Clinical Research Unlisted Share Price At Stockify
At Stockify, you get updated prices of Veeda Clinical Research Unlisted Shares, and the current Veeda Clinical Research Share Price Today is Rs. 499 per share. Keeping oneself updated with the costs of unlisted shares makes buying and selling easy. Since our experts possess a tremendous knowledge of the grey market, they update the prices whenever they get changed.
So log in and subscribe to our Finance Newsletter for regular stock updates.
Check Out Prices Of Other Unlisted Shares On Stockify
Are you interested in buying unlisted shares of other companies apart from Veeda Clinical? If yes, Stockify brings you a vast list of leading companies offering unlisted shares for potential investors to earn something big. You can choose the company to invest in the stock from manufacturing to healthcare, education, and energy. The companies you will find on Stockify are the best unlisted shares in India to buy. Just scroll through our list and get the updates on any unlisted company you’re looking for. For more information, we’re always here; connect with us.
Reliance Retail, Pharmeasy, Chennai super kings, Anglo-French Drugs & Industries, Hexaware Technologies Ltd, Five Star Business Finance Ltd Unlisted Shares, Fincare Small Finance Bank Ltd Unlisted Shares, Arohan Financial Services Unlisted Shares, Utkarsh Coreinvest Ltd Unlisted Shares, Fino Paytech Ltd Unlisted Shares, Hero Fincorp Ltd Unlisted Shares, National Stock Exchange Ltd Nse Unlisted Shares, National Commodity Derivatives Exchange Ltd Ncdex Unlisted Shares, MetroPolitan Stock Exchange MSEI Unlisted Shares, Capital, Small Finance Bank Ltd Unlisted Shares, And Motilal Oswal Home Finance Ltd Unlisted Shares.
Login To Buy Veeda Clinical Research Unlisted Share Price Today Live!
